Court Opinion

ID: 211154
Source: CourtListenerOpinion
Date Created: 2011-03-13 08:24:11+00
Date Added: 2024-06-11T17:28:04.963199
License: Public Domain

United States Court of Appeals for the Federal Circuit

                                         05-1374
                               (Interference No. 105,171)

                THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,

                                                     Appellant,

                                            v.

                  UNIVERSITY OF IOWA RESEARCH FOUNDATION
                   and COLEY PHARMACEUTICAL GROUP, INC.,

                                                     Appellees,

                                           and

                         THE UNITED STATES OF AMERICA
           (as represented by the Department of Health and Human Services),

                                                     Appellee.

       R. Danny Huntington, Bingham McCutchen LLP, of Washington, DC, argued for
appellant. With him on the brief was Malcolm K. McGowan.

      Lawrence M. Green, Wolf, Greenfield & Sacks, P.C., of Boston, Massachusetts,
argued for appellees, University of Iowa Research Foundation, et al. With him on the brief
were Edward R. Gates, John R. Van Amsterdam, and Laura Topper.

       Erica A. Franklin, Attorney, Intellectual Property Section, Commercial Litigation
Branch, Civil Division, United States Department of Justice, of Washington, DC, argued for
appellee, The United States of America. With her on the notice of joinder were Peter D.
Keisler, Assistant Attorney General, and John Fargo, Director. Of counsel was Susan L.
C. Mitchell.

Appealed from: United States Patent and Trademark Office, Board of Patent Appeals
               and Interferences
     United States Court of Appeals for the Federal Circuit
                                         05-1374
                               (Interference No. 105,171)

               THE REGENTS OF THE UNIVERSITY OF CALIFORNIA,

                                                        Appellant,

                                            v.

                  UNIVERSITY OF IOWA RESEARCH FOUNDATION
                   and COLEY PHARMACEUTICAL GROUP, INC.,

                                                        Appellees,

                                           and

                        THE UNITED STATES OF AMERICA
          (as represented by the Department of Health and Human Services),

                                                        Appellee.

                           ___________________________

                           DECIDED: July 17, 2006
                           ___________________________

Before RADER, BRYSON, and LINN, Circuit Judges.

RADER, Circuit Judge.

       The Board of Patent Appeals and Interferences (the Board) of the United States

Patent and Trademark Office (the PTO) resolved this interference between the Regents

of the University of California (California) as the senior party and the University of Iowa

Research Foundation, Coley Pharmaceutical Group, Inc., and the United States

(collectively, Iowa) as the junior party. The Board granted Iowa’s motion for judgment

that 35 U.S.C. § 135(b)(1) barred California’s sole claim interfering with Iowa’s U.S.

Patent No. 6,207,646 (the ’646 patent). Univ. of Iowa Research Found. v. Regents of
The Univ. of Cal., Interf. No. 105,171 (Bd. Pat. App. & Interf. Mar. 10, 2005) (Board

Decision). Because the Board correctly construed section 135(b)(1), this court affirms.

                                             I.

       The ’646 patent, entitled “Immunostimulatory Nucleic Acid Molecules,” issued on

March 27, 2001. That patent claims compositions and their use to minimize allergic

reactions. Specifically, claim 3 of the ’646 patent, the count in the interference, claims a

“method of desensitizing a subject against the occurrence of an allergic reaction.” ’646

patent, col. 61, ll. 51-52.   This method administers an allergen together with “an

effective amount of an immunostimulatory nucleic acid.” Id. at col. 61, ll. 53-61. Claim 3

of the ’646 patent further recites the particulars of the nucleic acid used in the claimed

method.

       When the ’646 patent issued, Application No. 09/265,191 (the ’191 application),

assigned to California, was pending before the PTO. On October 31, 2001, seven

months after Iowa’s ’646 patent issued, California added claims 202-204 to the ’191

application. Claims 202 and 203 recited immunostimulatory nucleic acid compositions,

while claim 204 recited a method of treating an allergy in a vertebrate including the

administration of an allergen together with an immunostimulatory nucleic acid. With the

addition of claims 202-204, California requested an interference with the ’646 patent. In

that request, California proposed that the interference include two counts, one to the

composition corresponding to claims 202 and 203, and the other to the method

corresponding to claim 204. In response to California’s amendment, the PTO rejected

claims 202-204.

05-1374                                      2
       California continued to prosecute the ’191 application after the rejection of claims

202-204, participating in multiple examiner interviews and responding to multiple

rejections. On May 9, 2002, more than one year after the ’646 patent had issued,

California added another method claim, claim 205, to the ’191 application. After more

prosecution, and another examiner interview, California canceled claims 202-204. The

PTO then declared an interference between claim 205 of California’s ’191 application

and Iowa’s ’646 patent. Claim 3 of the ’646 patent became the sole count.

       During the preliminary motions phase of the interference, Iowa filed a motion that

claim 205 was not patentable to California under 35 U.S.C. § 135(b)(1).              Board

Decision, slip op. at 4. Under 37 C.F.R. § 41.125(a) (allowing the Board to take up

motions for decision in any order), the Board opted to consider first the 35 U.S.C. §

135(b)(1) threshold issue. This issue, if decided in Iowa’s favor, would deny California

standing in the interference. Board Decision, slip op. at 22. In its decision, the Board

found that California filed claim 205 more than one year after the ’646 patent issued.

Therefore, unless California could link that claim to claims filed within a year of the ’646

issue date, section 135(b)(1) would bar claim 205 from the interference. Accordingly,

the Board examined claim 205 for material differences from California’s earlier claims.

Board Decision, slip op. at 12 (citing In re Berger, 279 F.3d 975, 981-82 (Fed. Cir.

2002)).

       The Board compared claim 205 with claims 202-203, Board Decision, slip op. at

14-16, and then with claim 204, id., slip op. at 16-20. The Board found that California’s

claim 205 contained material differences from claims 202-204. Therefore, claim 205

could not benefit from the earlier filing date of those claims. Id., slip op. at 16, 20.

05-1374                                      3
Thus, the Board concluded that 35 U.S.C. § 135(b)(1) barred California’s claim 205.

Accordingly, the Board granted Iowa’s motion for judgment on that basis. On appeal,

California does not contest the Board’s finding of material differences between claim

205 and claims 202-204. Instead, California challenges the Board’s conclusion that the

correct inquiry under § 135(b)(1) asks whether claims 202-204 contain material

differences from claim 205 and not whether claims 202-204 are to the same invention

as claims in the ’646 patent.

                                             II.

       The Board’s construction of 35 U.S.C. § 135(b)(1), the only question presented

on appeal, is a question of law that this court reviews without deference. In re Berger,

279 F.3d 975, 980 (Fed. Cir. 2002). Section 135(b)(1) states:

                     A claim which is the same as, or for the same or
              substantially the same subject matter as, a claim of an
              issued patent may not be made in any application unless
              such a claim is made prior to one year from the date on
              which the patent was granted.

35 U.S.C. § 135(b)(1) (2000). California argues that when it filed claims 202-204 within

a year of the issuance of the ’646 patent, it “discharged” its duty under section

135(b)(1). According to California, having already filed claims that satisfied section

135(b)(1), that section no longer bars any subsequent claim filed in the ’191 application.

Thus, California asserts that the proper 135(b)(1) test requires the Board to confine its

analysis to pre-critical date claims, where the “critical date” is the date one year after the

issuance of the patent relevant to the section 135(b)(1) analysis. Because California’s

proposed interpretation of section 135(b)(1) contravenes this court’s precedent, the

05-1374                                       4
plain meaning of the statute, and the policy underlying that section, this court rejects

those contentions.

       In Berger, relied on by the Board, this court applied section 135(b)(1) and

explained its implications. In Berger, the appellant had copied a claim from the Muller

patent more than one year after that patent had issued, amending his application to add

the copied claim as new claim 7. 279 F.3d at 978. The Board affirmed the examiner’s

rejection of claim 7 under section 135(b).1 The Board explained that the rejected claim

contained material differences from claims 1-6, which were on file before the critical

date. Id. at 980. On appeal, this court assessed the correctness of the Board’s test to

determine whether the earlier claims 1-6 supported claim 7. Id. at 981-82.

       Following Corbett v. Chisholm, 568 F.2d 759 (CCPA 1977), this court explained

that “[t]o establish entitlement to the earlier effective date of existing claims for purposes

of the one-year bar of 35 U.S.C. § 135(b), a party must show that the later filed claim

does not differ from an earlier claim in any ‘material limitation.’” Berger, 279 F.3d at

981-82 (quoting Corbett, 568 F.2d at 765-66) (emphasis added). Thus, opinions like

Berger, Corbett, and others, see, e.g., Cryns v. Musher, 161 F.2d 217 (CCPA 1947),

permit a party confronted with a section 135(b)(1) bar to show that claims filed after the

critical date find support in claims filed before the critical date. If a party can show such

       1
               In 1995, when the underlying patent application in Berger was pending
before the PTO, 35 U.S.C. § 135(b) did not include paragraphs (1) and (2). In 1999,
Congress amended section 135(b), designating the original paragraph (b) as paragraph
(b)(1), and adding paragraph (b)(2). Consolidated Appropriations Act, 2000, Pub. L. No.
106-113, § 1000(a)(9), 113 Stat. 1501 (1999). Thus, the pre-1999 section 135(b)
corresponds to the current section 135(b)(1). The difference between paragraphs (b)(1)
and (b)(2) is that the former creates a one year bar relative to issued patents, while the
latter creates a one year bar relative to published patent applications. Otherwise, the
two paragraphs are the same.

05-1374                                       5
support, section 135(b)(1) will not act as a bar. Berger, 279 F.3d at 981-82. Thus,

California’s position that the relationship between the post- and pre-critical date claims

is not relevant to section 135(b)(1) contravenes the weight of precedent. This court has

already explained that such a relationship is not only relevant, but dispositive of the

section 135(b)(1) question. Id.

       Moreover, this court does not perceive any legally significant distinctions

between this case and that precedent. For instance, California points out that when it

filed claims 202-204 within a year of the ’646 issuance it also requested an interference.

In Berger and Corbett, the record showed no such interference request before the

critical date in the applications at issue.      That factual distinction has no legal

significance. Section 135(b)(1) does not include any language suggesting that a pre-

critical date request for an interference makes any difference. Section 135(b)(1) bars

any claim having a degree of identity with a claim in an issued patent unless such a

claim is filed before the critical date. Thus, title 35 in this section does not demand

notice of an impending interference, but instead prohibits unsupported, post-critical date

identity.   California cannot satisfy section 135(b)(1) by supplying notice of an

interference. Instead, as this court’s precedent explains, California must demonstrate

that claims in the ’191 application provide pre-critical date support for the post-critical

date identity between claim 205 and the ’646 patent. That demonstration necessarily

entails a comparison between pre- and post-critical date claims. Finally, contrary to

California’s arguments, no language in Berger or Corbett suggests that the reason the

court compared the pre- and post-critical date claims in those cases was merely

because the record showed no request for interference within the critical time period. In

05-1374                                     6
short, the existence of a request for interference is not relevant to a proper section

135(b)(1) analysis.

         Neither In re Frey, 182 F.2d 184 (CCPA 1950), nor Thompson v. Hamilton, 152

F.2d 994 (CCPA 1946), both relied on by California, disturbs the correctness of the

approach in Berger. Without any detailed statutory analysis, Frey stated broadly: “[A]n

applicant for patent—if he had claims within the critical period to the same or

substantially the same subject matter as appears in a patent . . . is not barred from

copying claims from the patent [after the critical date.]” 182 F.2d at 185. As is apparent

from that quote, Frey dealt with the situation where the applicant added claims copied

from a patent. Thus, the claims added after the critical date in Frey were to the same

subject matter as the claims in the earlier issued patent. Likewise, in Thompson, the

issue confronting the court was the difference between “the counts” and the pre-critical

date claims. 152 F.2d at 997. As in Frey, the claims at issue in Thompson were copied

from the patent. See id. at 995. Thus, because both cases included post-critical date

claims that were the same as the patented claims, neither opinion is relevant to the

distinction between comparing pre- and post-critical date claims with one another and

comparing pre-critical date claims with the patented claims.

         Like this court’s precedent, the language of section 135(b)(1) does not support

California’s proposed construction.     California’s construction would convert section

135(b)(1) into a statute of limitations that could be tolled by a single pre-critical date

claim.    In essence, California contends that the phrase “such a claim” in section

135(b)(1) means any earlier claim that might have given notice of an interference had

the PTO declared such an interference. To the contrary, the statutory term “such a

05-1374                                     7
claim” refers to the claim that the potentially interfering party seeks to add, which is

directed to the same or substantially the same subject matter as that claimed in a

patent, regardless of whether that party earlier filed a different claim having the required

identity with a patented claim. The statute requires “such a claim” to come before the

critical date. Thus, section 135(b)(1) does not refer to some unrelated claim made

earlier in prosecution even if accompanied by a request for interference. The language

of the statute, “[a] claim . . . may not be made . . . unless such a claim is made prior to

. . . ,” necessarily requires that in the event a party seeks to add any claim sharing

identity with a patented claim, “such a claim” must appear before the critical date.

When a party seeks to add a new claim, or to amend an existing claim, beyond the

critical date for section 135(b)(1), this court applies the material differences test

discussed in opinions like Berger to determine if “such a claim” is barred. California’s

position that any claim filed within the critical time period supports, for section 135(b)(1)

purposes, any later added claims, regardless of the relationship between the pre- and

post-critical date claims, is simply not consistent with the language of the statute.

       The policy underlying section 135(b)(1) also supports the Board’s construction of

that section. This court and its predecessors have described section 135(b)(1) as a

statute of repose, placing a time limit on a patentee’s exposure to an interference

proceeding. See, e.g., Corbett, 568 F.2d at 765 (explaining that Congressional intent

behind the predecessor to section 135(b)(1), i.e., R.S. 4903, “was clearly to enact a

statute of repose . . . so that the patentee might be more secure in his property right”);

Berman v. Housey, 291 F.3d 1345, 1351 (Fed. Cir. 2002) (quoting Corbett).               This

general explanation, however, does not mean that a patent applicant can “discharge” its

05-1374                                      8
obligation under section 135(b)(1) for all future claims by filing any claim that once

complies with that section. Contrary to California’s arguments, section 135(b)(1) is not

a simple “notice statute” informing patentees about potential interference proceedings.

In fact, no notice at all is provided to the patentee by operation of section 135(b)(1)

itself. Rather, in order to serve as a statute of repose, section 135(b)(1) operates in

conjunction with the PTO’s duty to declare interferences. The filing of an interfering

claim and the subsequent declaration of an interference have a cause-and-effect

relationship. By limiting the time period for filing a potentially interfering claim, section

135(b)(1) limits the patentee’s vulnerability to a declaration of an interference only

because it limits the window of time in which the cause of the interference can occur.

The PTO should declare a valid interference upon receipt of a claim that satisfies

section 135(b)(1), and which is otherwise patentable.

       Despite the expected cause-and-effect relationship between the filing of an

interfering claim and the declaration of an interference, this court’s predecessor

observed that the PTO sometimes fails to declare an interference where one exists. As

Corbett explains, “[the PTO] should declare an interference whenever copending

applications claim substantially the same invention, and, if it fails to do so, the public

interest is better served by a belated interference than by the issuance of a second

patent.” 568 F.2d at 765. In other words, while an interference based on a post-critical

date claim is not desirable, where such an interference is merely belated, meaning the

same interference should have been earlier declared by the PTO, the interference

should not be barred by operation of section 135(b)(1). Thus, the limited exception to

the one year bar, provided by the “such a claim” language in section 135(b)(1), allows

05-1374                                      9
for belated interferences. Beyond such belated interferences, California’s construction

of section 135(b)(1) would permit different interferences because that construction

removes from section 135(b)(1) any requirement for a nexus between the pre- and post-

critical date claims.

       Finally, California suggests that the Board’s construction of section 135(b)(1) is

unfair to applicants who attempt to comply with that section only to have their claims

rejected during ex parte examination more than a year after the issuance of the patent

with which they are seeking an interference. According to California, this result unfairly

denies an applicant access to an interference just because, for example, the pre-critical

date claims added to provoke the interference lacked written description support, and

hence were rejected by the PTO. To the contrary, this court perceives no inequity in a

construction of section 135(b)(1) that might, in some circumstances, prevent a patent

applicant from relying on the filing date of a claim to which it was not statutorily entitled.

                                       CONCLUSION

       Because the Board properly construed 35 U.S.C. § 135(b)(1), this court affirms.

                                           COSTS

       Each party shall bear its own costs.

                                         AFFIRMED

05-1374                                       10